Neurotech International Ltd

Company Profile

• Business description

  Neurotech International Ltd is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), along with Rett Syndrome.

• Contact

  55 Collins Street
  Suite 102, Level 1
  MelbourneVIC3000
  AUS

  T: +61 394983132

  https://www.neurotechinternational.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  Employees

  18